Dung-Tsa Chen
Overview
Explore the profile of Dung-Tsa Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
128
Citations
3082
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Meng L, Cao B, Ji R, Chen D, Laber D, Shafique M
J Cancer
. 2023 Nov;
14(17):3169-3175.
PMID: 37928431
Large Cell Neuroendocrine Carcinoma (LCNEC) is a high-grade malignancy with limited treatment options. Despite promising results of immunotherapy in non-small cell and small cell lung cancers, its benefit in LCNEC...
12.
Ravi H, Hawkins S, Stringfield O, Pereira M, Chen D, Enderling H, et al.
Res Sq
. 2023 Oct;
PMID: 37790451
We report domain knowledge-based rules for assigning voxels in brain multiparametric MRI (mpMRI) to distinct tissuetypes based on their appearance on Apparent Diffusion Coefficient of water (ADC) maps, T1-weighted unenhanced...
13.
Amorrortu R, Garcia M, Zhao Y, El Naqa I, Balagurunathan Y, Chen D, et al.
JNCI Cancer Spectr
. 2023 Sep;
7(6).
PMID: 37738580
Background: Randomized clinical trials of novel treatments for solid tumors normally measure disease progression using the Response Evaluation Criteria in Solid Tumors. However, novel, scalable approaches to estimate disease progression...
14.
Obermayer A, Chang D, Nobles G, Teng M, Tan A, Wang X, et al.
BMC Bioinformatics
. 2023 Jun;
24(1):266.
PMID: 37380943
Pathway-level survival analysis offers the opportunity to examine molecular pathways and immune signatures that influence patient outcomes. However, available survival analysis algorithms are limited in pathway-level function and lack a...
15.
Chen D, Saltos A, Rose T, Thompson Z, Thapa R, Chiappori A, et al.
Cancers (Basel)
. 2023 May;
15(9).
PMID: 37173987
Rationale: Adverse events (AEs) have been shown to have clinical associations, in addition to patient safety assessments of drugs of interest. However, due to their complex content and associated data...
16.
Echevarria M, Yang G, Chen D, Kirtane K, Russell J, Kish J, et al.
Int J Radiat Oncol Biol Phys
. 2023 Apr;
117(2):341-347.
PMID: 37105404
Purpose: Patients with locoregional recurrence of squamous cell carcinoma of the head and neck (SCCHN) have relatively poor outcomes; therefore, stereotactic body radiation therapy (SBRT) has been investigated for this...
17.
Obermayer A, Chang D, Nobles G, Teng M, Tan A, Wang X, et al.
Res Sq
. 2023 Mar;
PMID: 36993526
Pathway-level survival analysis offers the opportunity to examine molecular pathways and immune signatures that influence patient outcomes. However, available survival analysis algorithms are limited in pathway-level function and lack a...
18.
Saller J, White D, Hough B, Yoder S, Whiting J, Chen D, et al.
Cancer Genomics Proteomics
. 2023 Mar;
20(2):154-164.
PMID: 36870693
Background/aim: Grading pancreatic neuroendocrine neoplasms (PNENs) via mitotic rate and Ki-67 index score is complicated by interobserver variability. Differentially expressed miRNAs (DEMs) are useful for predicting tumour progression and may...
19.
Tanvetyanon T, Chen D, Gray J
J Clin Med
. 2023 Feb;
12(4).
PMID: 36836146
Background: Pembrolizumab monotherapy or pembrolizumab plus chemotherapy has become an important frontline treatment for advanced non-small cell lung cancer (NSCLC). To date, it remains unclear how the coronavirus disease 2019...
20.
Rivera-Rivera Y, Vargas G, Jaiswal N, Nunez-Marrero A, Li J, Chen D, et al.
Cell Div
. 2022 Dec;
17(1):6.
PMID: 36494865
Molecular epidemiology evidence indicates racial and ethnic differences in the aggressiveness and survival of breast cancer. Hispanics/Latinas (H/Ls) and non-Hispanic Black women (NHB) are at higher risk of breast cancer...